Vaxcyte, Inc.
PCVX
Rank in Stocks
#2069
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Share Price
$65.22
Market Cap
$10.00B
Change (1 day)
2.51%
Change (1 year)
53.86%
Country
US
Trade Vaxcyte, Inc. (PCVX)
Category
Healthcare
Number of shares outstanding for Vaxcyte, Inc. (PCVX)
Number of shares outstanding as of June 2026: 144.49M
According to Vaxcyte, Inc. latest financial reports and stock price the company's current number of shares outstanding is 144.49M. At the end of December 2023 the company had 97.16M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Vaxcyte, Inc. (PCVX) from 2017 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 144.49M | 18.44% |
| 2024 | 122.00M | 25.57% |
| 2023 | 97.16M | 49.75% |
| 2022 | 64.88M | 24.95% |
| 2021 | 51.92M | 75.74% |
| 2020 | 29.55M | 678.52% |
| 2019 | 3.80M | 4.57% |
| 2018 | 3.63M | 1.80% |
| 2017 | 3.57M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 75.72% |
US
|
|
| 396.00M | 174.06% |
US
|
|
| 478.91M | 231.44% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -56.96% |
NL
|
